UK-based Mundipharma has agreed a deal worth up to $600 million to acquire exclusive Japanese rights for Invossa (TissueGene-C) with South Korean firm Kolon Life Science. 19 November 2018
UK-headquartered commercial-stage biotech firm Orchard Therapeutics today announced two additions to its global commercial leadership team, appointing Robin Kenselaar as senior vice president and general manager, EMEA commercial operations, and Brad Mathis as vice president, US commercial operations. 8 November 2018
When Per Falk, Ferring’s chief science officer, assumes the additional responsibility of becoming president of the executive committee on January 1 next year, he will be the envy of many big pharma leaders. 5 November 2018
Michel Pettigrew, the most senior officer at privately-held drugmaker Ferring, is to retire at the end of the year, the Switzerland-based company has announced. 31 October 2018
US biotech Celgene has appointed Dr Alise Reicin as president, global clinical development, reporting to Mark Alles, chairman and chief executive, effective November 1, 2018. 24 October 2018
Simon Jose, a Brit who has spent more than 30 years in pharma, is to become chief commercial officer of Idorsia, the research-based spin-out from Actelion following the latter’s acquisition by Johnson & Johnson. 23 October 2018
Swedish firm Medivir has announced that Uli Hacksell will replace Christine Lind as chief executive, with immediate effect, just 18 months after she took up the position. 16 October 2018
Jesper Brandgaard (pictured above) is to retire after 20 years with Danish pharma major Novo Nordisk, vacating the role of executive vice president, Biopharm and Legal Affairs. 15 October 2018
Incoming Pfizer chief executive Albert Bourla is to stamp his mark firmly on the company’s leadership, as the firm announced a new executive team ready to clock on from the commencement of his tenure next year. 10 October 2018
Ireland-headquartered generic and OTC drugmaker Perrigo, which recently said it was restructuring into two separate units, has announced the appointment of Murray Kessler as president, chief executive and member of the board of directors, effective immediately. 10 October 2018
The Mundipharma network of independent associated companies today confirmed the appointment of Philippe Bastide, who joins as head of biosimilars, Mint Commercial. 5 October 2018
Ian Read’s eight-year stint as chief executive of the world’s biggest pharma company will come to an end in three months time, when he will be replaced by current chief operating officer (COO), Albert Bourla. 1 October 2018
German pharma major Bayer has appointed Sebastian Guth as president of Pharmaceuticals, Americas Region, comprising the USA, Canada, Central and Latin America, effective December 1, 2018. 28 September 2018
Carri Duncan has left her role as senior investor relations manager with German pharma major Bayer to join the CAR-T specialist Celyad. 27 September 2018
Adam Keeney has been appointed president and chief executive of NodThera, a biotech focused on the discovery and development of NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. 24 September 2018
San Franciscan microbial genomics specialist uBiome has raised $83 million in a series C financing round directed at funding an expansion into therapeutics. 21 September 2018
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024